BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study
October 18, 2021 07:00 ET
|
BiomX
12-Week Study of BX001 Meets Safety and Tolerability Endpoints Statistically Significant Improvement from Baseline Observed in Appearance of Acne-prone Skin but No Meaningful Difference Demonstrated...
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
October 13, 2021 07:00 ET
|
BiomX
BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and...
BiomX to Present at Upcoming September Investor Conferences
September 02, 2021 16:05 ET
|
BiomX
BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural...
BiomX Reports Second Quarter 2021 Financial Results and Provides Business Update
August 16, 2021 06:30 ET
|
BiomX
Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023 Expecting Four Clinical Data Readouts by Mid-2022 Company Will Host a Conference Call and Webcast Today...
BiomX to Host Second Quarter 2021 Financial Results Conference Call and Webcast on August 16, 2021
August 12, 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Inc. Announces $15 Million Registered Direct Offering
July 26, 2021 08:13 ET
|
BiomX
NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX To Host Key Opinion Leader Event on BX003 for the Treatment of Inflammatory Bowel Disease
May 18, 2021 08:00 ET
|
BiomX
NESS ZIONA, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage...
BiomX Hosting Key Opinion Leader Symposium on Novel Phage Product for Acne Prone Skin
September 09, 2019 08:00 ET
|
BiomX
NESS ZIONA, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that it will host a Key Opinion Leader...